USD 26.17
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| NVCR | 0.6 | -4.7 | -17.0 | 52.1 | 41.6 | 80.5 | -59.4 | -72.6 | 19.0 | 19.0 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | NVCR |
| name | NovoCure Limited |
| price | 26.17 |
| changes percentage | 0.5765 |
| change | 0.15 |
| day low | 25.66 |
| day high | 27.105 |
| year high | 34.13 |
| year low | 11.7 |
| market cap | 2831620170 |
| price avg 50 | 25.0418 |
| price avg 200 | 19.442924 |
| exchange | NASDAQ |
| volume | 1156083 |
| avg volume | 1257175 |
| open | 25.99 |
| previous close | 26.02 |
| eps | -1.39 |
| pe | -18.83 |
| earnings announcement | 2025-02-27T13:30:00.000+0000 |
| shares outstanding | 108201000 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645113 | |||
| revenue | 509338000 | 537840000 | -5.30 |
| gross profit | 381058000 | 422973000 | -9.91 |
| gross profit ratio | 0.75 | 0.79 | -4.87 |
| research and development expenses | 223062000 | 206085000 | 8.24 |
| operating expenses | 614673000 | 512496000 | 19.94 |
| interest income | 46036000 | 10961000 | 320.00 |
| interest expense | 3319000 | 3334000 | -0.45 |
| ebitda | -175865000 | -63109000 | -178.67 |
| ebitdaratio | -0.35 | -0.17 | -107.44 |
| operating income | -232870000 | -89523000 | -160.12 |
| operating income ratio | -0.46 | -0.17 | -174.68 |
| net income | -207043000 | -92534000 | -123.75 |
| net income ratio | -0.41 | -0.17 | -136.27 |
| eps | -1.95 | -0.88 | -121.59 |
Revenue Growth: revenue decreased to 509 million in 2023 from 538 million in 2022 representing a change of -5.3%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 381 million in 2023 from 423 million in 2022 representing a change of -9.91%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 615 million in 2023 from 512 million in 2022 representing a change of 19.94%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -176 million in 2023 from -63 million in 2022 representing a change of -178.67%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -233 million in 2023 from -90 million in 2022 representing a change of -160.12%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -207 million in 2023 from -93 million in 2022 representing a change of -123.75%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.95 in 2023 from -1.95 in 2022 representing a change of -121.59%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 223 million in 2023 from 206 million in 2022 representing a change of 8.24%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645113 | |||
| revenue | 155095000 | 150356000 | 3.15 |
| gross profit | 119723000 | 115702000 | 3.48 |
| gross profit ratio | 0.77 | 0.77 | 0.31 |
| research and development expenses | 51882000 | 54955000 | -5.59 |
| operating expenses | 151815000 | 149309000 | 1.68 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | -29634000 | -30749000 | 3.63 |
| ebitdaratio | -0.19 | -0.2 | 6.57 |
| operating income | -32092000 | -33607000 | 4.51 |
| operating income ratio | -0.21 | -0.22 | 7.43 |
| net income | -30570000 | -33375000 | 8.40 |
| net income ratio | -0.2 | -0.22 | 11.20 |
| eps | -0.28 | -0.31 | 9.68 |
Revenue Growth: revenue increased to 155 million in 2024Q3 from 150 million in 2024Q2 representing a change of 3.15%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 120 million in 2024Q3 from 116 million in 2024Q2 representing a change of 3.48%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -0.28 in 2024Q3 from -0.28 in 2024Q2 representing a change of 9.68%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 52 million in 2024Q3 from 55 million in 2024Q2 representing a change of -5.59%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 152 million in 2024Q3 from 149 million in 2024Q2 representing a change of 1.68%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -30 million in 2024Q3 from -31 million in 2024Q2 representing a change of 3.63%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -32 million in 2024Q3 from -34 million in 2024Q2 representing a change of 4.51%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -31 million in 2024Q3 from -33 million in 2024Q2 representing a change of 8.4%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645113 | |||
| total assets | 1146129000 | 1191648000 | -3.82 |
| total liabilities | 783633000 | 750478000 | 4.42 |
| total equity | 362496000 | 441170000 | -17.83 |
| cash and cash equivalents | 240821000 | 115326000 | 108.82 |
| short term investments | 669795000 | 854099000 | -21.58 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1034409000 | 1111529000 | -6.94 |
| total non current assets | 111720000 | 80119000 | 39.44 |
| total current liabilities | 179115000 | 158777000 | 12.81 |
| total non current liabilities | 604518000 | 591701000 | 2.17 |
| common stock | 0 | 0 | NaN |
| retained earnings | -985503000 | -778460000 | -26.60 |
| total debt | 596242000 | 584271000 | 2.05 |
Total Assets: Total Assets decreased to 1,146 million in 2023 from 1,192 million in 2022 representing a change of -3.82%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 784 million in 2023 from 750 million in 2022 representing a change of 4.42%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 362 million in 2023 from 441 million in 2022 representing a change of -17.83%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 670 million in 2023 from 854 million in 2022 representing a change of -21.58%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 1,034 million in 2023 from 1,112 million in 2022 representing a change of -6.94%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 179 million in 2023 from 159 million in 2022 representing a change of 12.81%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -986 million in 2023 from -778 million in 2022 representing a change of -26.6%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 596 million in 2023 from 584 million in 2022 representing a change of 2.05%. This indicates an increase in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 241 million in 2023 from 115 million in 2022 representing a change of 108.82%. This indicates an increase in available liquid assets.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645113 | |||
| total assets | 1221986000 | 1212170000 | 0.81 |
| total liabilities | 861205000 | 850420000 | 1.27 |
| total equity | 360781000 | 361750000 | -0.27 |
| cash and cash equivalents | 185422000 | 168443000 | 10.08 |
| short term investments | 774476000 | 786390000 | -1.52 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1095268000 | 1092836000 | 0.22 |
| total non current assets | 126718000 | 119334000 | 6.19 |
| total current liabilities | 735002000 | 169178000 | 334.45 |
| total non current liabilities | 126203000 | 681242000 | -81.47 |
| common stock | 0 | 0 | NaN |
| retained earnings | -1088208000 | -1057637999 | -2.89 |
| total debt | 675626000 | 675201000 | 0.06 |
Total Assets: Total Assets increased to 1,222 million in 2024Q3 from 1,212 million in 2024Q2 representing a change of 0.81%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 185 million in 2024Q3 from 168 million in 2024Q2 representing a change of 10.08%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,095 million in 2024Q3 from 1,093 million in 2024Q2 representing a change of 0.22%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 861 million in 2024Q3 from 850 million in 2024Q2 representing a change of 1.27%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 361 million in 2024Q3 from 362 million in 2024Q2 representing a change of -0.27%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 774 million in 2024Q3 from 786 million in 2024Q2 representing a change of -1.52%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 735 million in 2024Q3 from 169 million in 2024Q2 representing a change of 334.45%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,088 million in 2024Q3 from -1,058 million in 2024Q2 representing a change of -2.89%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 676 million in 2024Q3 from 675 million in 2024Q2 representing a change of 0.06%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645113 | |||
| net change in cash | 126730000 | -93775000 | 235.14 |
| operating cash flow | -73336000 | 30788000 | -338.20 |
| free cash flow | -100429000 | 9430000 | -1164.99 |
| capital expenditure | -27093000 | -21358000 | -26.85 |
| depreciation and amortization | 10969000 | 10624000 | 3.25 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 115608000 | 106955000 | 8.09 |
| accounts payables | 14869000 | 14257000 | 4.29 |
| inventory | -8919000 | -4342000 | -105.41 |
| acquisitions net | 0 | 118599000 | -100.00 |
| investments in property plant and equipment | -27093000 | -21358000 | -26.85 |
| net cash used for investing activites | 184148000 | -139957000 | 231.57 |
| debt repayment | -10000 | -28000 | 64.29 |
| common stock issued | 4416000 | 5224000 | -15.47 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 15787000 | 15491000 | 1.91 |
| cash at end of period | 242564000 | 115834000 | 109.41 |
| accounts receivables | 29414000 | 2547000 | 1054.85 |
| cash at beginning of period | 115834000 | 209609000 | -44.74 |
Net Change in Cash: Net Change in Cash increased to 127 million in 2023 from -94 million in 2022 representing a change of 235.14%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -27 million in 2023 from -21 million in 2022 representing a change of -26.85%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Operating Cash Flow: Operating Cash Flow decreased to -73 million in 2023 from 31 million in 2022 representing a change of -338.2%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -100 million in 2023 from 9 million in 2022 representing a change of -1164.99%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 116 million in 2023 from 107 million in 2022 representing a change of 8.09%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 15 million in 2023 from 14 million in 2022 representing a change of 4.29%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 29 in 2023 from 3 million in 2022 representing a change of 1054.85%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645113 | |||
| operating cash flow | 10376000 | -1720000 | 703.26 |
| free cash flow | -307000 | -13166000 | 97.67 |
| capital expenditure | -10683000 | -11446000 | 6.67 |
| depreciation and amortization | 2458000 | 2858000 | -14.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 31364000 | 31830000 | -1.46 |
| accounts receivables | 5411000 | -11119000 | 148.66 |
| accounts payables | 7452000 | 9548000 | -21.95 |
| inventory | 1895000 | 1888000 | 0.37 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -10683000 | -11446000 | 6.67 |
| net cash used for investing activites | 10193000 | -374440000 | 102.72 |
| debt repayment | 0 | 84009000 | -100.00 |
| common stock issued | 100000 | 2187000 | -95.43 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 100000 | 87317000 | -99.89 |
| net change in cash | 20756000 | -288920000 | 107.18 |
| cash at end of period | 189199000 | 168443000 | 12.32 |
| cash at beginning of period | 168443000 | 457363000 | -63.17 |
Net Change in Cash: Net Change in Cash increased to 21 million in 2024Q3 from -289 million in 2024Q2 representing a change of 107.18%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 10 million in 2024Q3 from -2 million in 2024Q2 representing a change of 703.26%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 0 million in 2024Q3 from -13 million in 2024Q2 representing a change of 97.67%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 31 million in 2024Q3 from 32 million in 2024Q2 representing a change of -1.46%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 7 million in 2024Q3 from 10 million in 2024Q2 representing a change of -21.95%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -11 million in 2024Q3 from -11 million in 2024Q2 representing a change of 6.67%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 5 in 2024Q3 from -11 million in 2024Q2 representing a change of 148.66%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 4.79 | 5.14 | -6.84 |
| net income per share | -1.95 | -0.88 | -120.11 |
| operating cash flow per share | -0.69 | 0.29 | -334.32 |
| free cash flow per share | -0.94 | 0.09 | -1147.67 |
| cash per share | 8.56 | 9.26 | -7.59 |
| book value per share | 3.41 | 4.22 | -19.17 |
| tangible book value per share | 3.41 | 4.22 | -19.17 |
| shareholders equity per share | 3.41 | 4.22 | -19.17 |
| interest debt per share | 5.64 | 5.61 | 0.37 |
| market cap | 1588420287.54 | 7676845914.6 | -79.31 |
| enterprise value | 1943841287.54 | 8145790914.6 | -76.14 |
| pe ratio | -7.67 | -82.96 | 90.75 |
| price to sales ratio | 3.12 | 14.27 | -78.15 |
| pocfratio | -21.66 | 249.35 | -108.69 |
| pfcf ratio | -15.82 | 814.09 | -101.94 |
| pb ratio | 4.38 | 17.4 | -74.82 |
| ptb ratio | 4.38 | 17.4 | -74.82 |
| ev to sales | 3.82 | 15.15 | -74.80 |
| enterprise value over ebitda | -11.05 | -129.07 | 91.44 |
| ev to operating cash flow | -26.51 | 264.58 | -110.02 |
| ev to free cash flow | -19.36 | 863.82 | -102.24 |
| earnings yield | -0.13 | -0.01 | -981.38 |
| free cash flow yield | -0.06 | 0.0 | -5247.13 |
| debt to equity | 1.64 | 1.32 | 24.20 |
| debt to assets | 0.52 | 0.49 | 6.10 |
| net debt to ebitda | -2.02 | -7.43 | 72.80 |
| current ratio | 5.78 | 7.0 | -17.51 |
| interest coverage | -70.16 | -26.85 | -161.30 |
| income quality | 0.35 | -0.33 | 206.46 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.32 | 0.25 | 30.50 |
| research and ddevelopement to revenue | 0.44 | 0.38 | 14.29 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.37 | 0.69 | -153.26 |
| capex to revenue | 0.05 | 0.04 | 33.95 |
| capex to depreciation | 2.47 | 2.01 | 22.86 |
| stock based compensation to revenue | 0.23 | 0.2 | 14.14 |
| graham number | 12.21 | 9.16 | 33.38 |
| roic | -0.26 | -0.1 | -165.36 |
| return on tangible assets | -0.18 | -0.08 | -132.63 |
| graham net net | 1.92 | 2.85 | -32.77 |
| working capital | 855294000 | 952752000 | -10.23 |
| tangible asset value | 362496000 | 441170000 | -17.83 |
| net current asset value | 250776000 | 361051000 | -30.54 |
| invested capital | 952992000 | 1021710000 | -6.73 |
| average receivables | 81687500 | 89914000 | -9.15 |
| average payables | 89794000 | 78898500 | 13.81 |
| average inventory | 33764000 | 26901500 | 25.51 |
| days sales outstanding | 55.26 | 58.54 | -5.60 |
| days payables outstanding | 268.57 | 270.72 | -0.79 |
| days of inventory on hand | 108.56 | 93.34 | 16.29 |
| receivables turnover | 6.61 | 6.24 | 5.93 |
| payables turnover | 1.36 | 1.35 | 0.80 |
| inventory turnover | 3.36 | 3.91 | -14.01 |
| roe | -0.57 | -0.21 | -172.31 |
| capex per share | 0.25 | 0.2 | 24.79 |
ROE: Return on Equity (ROE) decreased to -0.57 on 2023-12-31 from -0.21 on 2022-12-31, representing a change of -172.31%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 5.78 on 2023-12-31 from 7.00 on 2022-12-31, representing a change of -17.51%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -7.67 on 2023-12-31 from -82.96 on 2022-12-31, representing a change of 90.75%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio:
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| NVCR | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.43 | 1.4 | 2.63 |
| net income per share | -0.28 | -0.31 | 8.87 |
| operating cash flow per share | 0.1 | -0.02 | 700.21 |
| free cash flow per share | -0.0 | -0.12 | 97.68 |
| cash per share | 8.87 | 8.87 | 0.02 |
| book value per share | 3.33 | 3.36 | -0.77 |
| tangible book value per share | 3.33 | 3.36 | -0.77 |
| shareholders equity per share | 3.33 | 3.36 | -0.77 |
| interest debt per share | 6.24 | 6.27 | -0.44 |
| market cap | 1691911801.08 | 1868599927.4 | -9.46 |
| enterprise value | 2182115801.08 | 2375357927.4 | -8.14 |
| pe ratio | -13.84 | -14.0 | 1.15 |
| price to sales ratio | 10.91 | 12.43 | -12.22 |
| pocfratio | 163.06 | -1086.4 | 115.01 |
| pfcf ratio | -5511.11 | -141.93 | -3783.08 |
| pb ratio | 4.69 | 5.17 | -9.21 |
| ptb ratio | 4.69 | 5.17 | -9.21 |
| ev to sales | 14.07 | 15.8 | -10.94 |
| enterprise value over ebitda | -73.64 | -77.25 | 4.68 |
| ev to operating cash flow | 210.3 | -1381.02 | 115.23 |
| ev to free cash flow | -7107.87 | -180.42 | -3839.71 |
| earnings yield | -0.02 | -0.02 | -1.16 |
| free cash flow yield | -0.0 | -0.01 | 97.42 |
| debt to equity | 1.87 | 1.87 | 0.33 |
| debt to assets | 0.55 | 0.56 | -0.74 |
| net debt to ebitda | -16.54 | -16.48 | -0.37 |
| current ratio | 1.49 | 6.46 | -76.93 |
| interest coverage | 0 | 0 | NaN |
| income quality | -0.34 | 0.05 | -758.61 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.26 | 0.25 | 3.09 |
| research and ddevelopement to revenue | 0.33 | 0.37 | -8.48 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 1.03 | -6.65 | 115.47 |
| capex to revenue | 0.07 | 0.08 | -9.52 |
| capex to depreciation | 4.35 | 4.0 | 8.52 |
| stock based compensation to revenue | 0.2 | 0.21 | -4.47 |
| graham number | 4.6 | 4.84 | -4.91 |
| roic | -0.04 | -0.05 | 8.01 |
| return on tangible assets | -0.03 | -0.03 | 9.14 |
| graham net net | 1.56 | 1.61 | -3.16 |
| working capital | 360266000 | 923658000 | -61.00 |
| tangible asset value | 360781000 | 361750000 | -0.27 |
| net current asset value | 234063000 | 242416000 | -3.45 |
| invested capital | 474760000 | 1030930000 | -53.95 |
| average receivables | 65881500 | 64896999.5 | 1.52 |
| average payables | 90745000 | 87243500 | 4.01 |
| average inventory | 39769000 | 41416500 | -3.98 |
| days sales outstanding | 38.91 | 38.73 | 0.48 |
| days payables outstanding | 232.35 | 234.18 | -0.78 |
| days of inventory on hand | 99.48 | 105.03 | -5.29 |
| receivables turnover | 2.31 | 2.32 | -0.47 |
| payables turnover | 0.39 | 0.38 | 0.79 |
| inventory turnover | 0.9 | 0.86 | 5.59 |
| roe | -0.08 | -0.09 | 8.16 |
| capex per share | 0.1 | 0.11 | -7.14 |
ROE: Return on Equity (ROE) increased to -0.08 on 2024-09-30 Q3 from -0.09 on 2024-06-30 Q2, representing a change of 8.16%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -13.84 on 2024-09-30 Q3 from -14.00 on 2024-06-30 Q2, representing a change of 1.15%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.49 on 2024-09-30 Q3 from 6.46 on 2024-06-30 Q2, representing a change of -76.93%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio:
Negative Sentiment: Discounted Cash Flow value is 0.76 which is lower than current price 26.17, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Neutral
Publish Date: 2025-01-13 07:00:00
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.
Sentiment: Neutral
Publish Date: 2025-01-03 07:00:00
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.
Sentiment: Positive
Publish Date: 2024-12-06 08:32:03
Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
Sentiment: Positive
Publish Date: 2024-12-05 04:29:00
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.
Sentiment: Positive
Publish Date: 2024-12-04 21:59:44
NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite past challenges, NVCR's recent positive data, strong commercial numbers, and robust cash position suggest a potential turnaround and long-term growth. Key upcoming catalysts include FDA submission and potential approval for pancreatic cancer, with a strong cash position supporting continued development and commercialization efforts.
Sentiment: Negative
Publish Date: 2024-12-03 11:01:24
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Sentiment: Negative
Publish Date: 2024-12-02 13:10:13
Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory submissions, of TTFields therapy combination targeting locally advanced 1st-line pancreatic cancer patients, expected throughout 2025. Data from phase 2 PANOVA-4 trial, using TTFields + TECENTRIQ + Gemcitabine + Nab-paclitaxel to treat 1st-line metastatic pancreatic cancer patients, expected in 2026.
Sentiment: Negative
Publish Date: 2024-12-02 10:12:00
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Sentiment: Negative
Publish Date: 2024-12-02 08:57:50
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer. The post Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds appeared first on Investor's Business Daily.
Sentiment: Negative
Publish Date: 2024-12-02 07:17:29
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage trial.
Sentiment: Negative
Publish Date: 2024-12-02 07:02:00
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv.
Sentiment: Negative
Publish Date: 2024-12-02 07:00:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer.
Sentiment: Neutral
Publish Date: 2024-11-27 07:00:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.
Sentiment: Positive
Publish Date: 2024-11-21 07:05:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma.
Sentiment: Positive
Publish Date: 2024-11-21 07:00:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--FDA approves Novocure's Innovative HFE transducer arrays for use with Optune Gio® for glioblastoma.
Sentiment: Positive
Publish Date: 2024-10-30 11:53:06
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.
Sentiment: Negative
Publish Date: 2024-10-30 09:16:13
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-10-30 07:02:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer.
Sentiment: Neutral
Publish Date: 2024-10-30 07:00:00
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
